Industry News
Pharmaceutical Industry News
Eli Lilly emerged as the “clear…
Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”
Actress Mariska Hargitay looks…
Actress Mariska Hargitay looks back on her late father's multiple myeloma journey in BMS' "Investigate Myeloma" campaign, highlighting its emerging CELMoD research.
For Novo Nordisk, the launch of…
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the chronic weight management market
The FDA has expanded the label for…
The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor
Hikma Pharmaceuticals plans to…
Hikma Pharmaceuticals plans to spend $267 million to expand a pair of manufacturing facilities in Ohio as part of the $1 billion the U.K. drugmaker committed a year ago to build out its U.S. operations.
As Amgen strives to become the top…
As Amgen strives to become the top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past
The company adjusted its full-year…
The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).
The FDA is going forward with…
The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative that could allow the Trump administration to impose restrictions on its use, The Wall Street Journal reports.
Each year, the global oncology…
Each year, the global oncology community descends on Chicago for ASCO, where buzzy data drops, practice-changing posters and packed sessions offer a look at where cancer care is headed next. In this week’s episode of
With a resounding unanimous vote,…
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.
The drumbeat of news regarding…
The drumbeat of news regarding Asian pharma—and particularly China—continues to grow louder. At the American Society of Clinical Oncology (ASCO) meeting, Akeso took center stage with an ivonescimab presentation, and Fierce’s Angus Liu took a
The platform was built in…
The platform was built in collaboration with Vertex Pharmaceuticals, a biopharma company that launched a non-opioid pain reliever in early 2025.
Three times as many deaths in the…
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market since
The company inked another…
The company inked another settlement with a prospective generic maker, leaving no further pending patent litigation for its Sunosi on the table.
Medical device distribution giant…
Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the presence of toxic bacteria in
In response to a planned…
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least
As its ultra-rare disease med…
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pick disease type C into one resembling
Cencora and Gilead have expanded…
Cencora and Gilead have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to the CAR-T cancer therapies Yescarta and Tecartus.
There were 487 booths at the…
There were 487 booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting in Chicago’s McCormick Place. Fierce Pharma Marketing attempted to see them all.
The words used to describe disease…
The words used to describe disease can shape how patients are diagnosed, treated and understood. From mpox to obesity to the Fitzpatrick scale, outdated or imprecise language can deepen stigma and obscure the full scope